Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy (Nature Communications (2015) 6:6220 doi: 10.1038/ncomms7220);Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy

Nature Communications

Volumn 6, Issue , 2015, Pages

  Kenny, Hilary A ^a   Lal Nag, Madhu ^b   White, Erin A ^a   Shen, Min ^b   Chiang, Chun Yi ^a   Mitra, Anirban K ^a   Zhang, Yilin ^a   Curtis, Marion ^a   Schryver, Elizabeth M ^a   Bettis, Sam ^c   Jadhav, Ajit ^b   Boxer, Matthew B ^b   Li, Zhuyin ^b,d   Ferrer, Marc ^b   Lengyel, Ernst ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXIDINE; BETA ESCIN; CANTHARIDIN; CARBOPLATIN; CISPLATIN; CYTOKERATIN; DOCETAXEL; PACLITAXEL; TOMATINE; VIMENTIN; ANTINEOPLASTIC AGENT; BENZOPHENANTHRIDINE DERIVATIVE; BIGUANIDE DERIVATIVE; ESCIN; ISOQUINOLINE DERIVATIVE; PROCHLORPERAZINE; SANGUINARINE;

BIOASSAY; BIOLOGICAL INVASION; CANCER; CELL ORGANELLE; DEVELOPMENTAL BIOLOGY; DRUG RESISTANCE; GROWTH RATE; INHIBITOR; NUMERICAL MODEL; THREE-DIMENSIONAL MODELING; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BIOASSAY; CANCER CELL; CANCER SURVIVAL; CELL ADHESION; CELL COUNT; CELL CULTURE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESOTHELIUM CELL; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY METASTASIS; PRIMARY CELL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; ANIMAL; CELL MOTION; CHEMISTRY; COCULTURE; DEVICES; DRUG EFFECTS; EPITHELIUM CELL; IC50; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPHENANTHRIDINES; BIGUANIDES; CANTHARIDIN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; COCULTURE TECHNIQUES; EPITHELIAL CELLS; ESCIN; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MICE; MICE, NUDE; OVARIAN NEOPLASMS; PRIMARY CELL CULTURE; PROCHLORPERAZINE; TOMATINE; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923197615     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10649     Document Type: Erratum

References (35)

1. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437 (2013).
2. Correia, A. L. & Bissell, M. J. The tumor microenvironment is a dominant force in multidrug resistance. Drug. Resist. Updat. 15, 39-49 (2012).
3. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cell recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012).
4. Nieman, K. M., Romero, I. L., Van Houten, B. & Lengyel, E. Adipocyte tissue and adipocytes support tumorigenesis and metastasis. Biochim. Biophys. Acta 1831, 1533-1541 (2013).
5. Zang, R., Ding, L., Tang, I. C., Wang, J. & Yang, S. T. Cell-based assays in high-throughput screening for drug discovery. Int. J. Biotechnol. Wellness Ind. 1, 31-51 (2012).
6. An, W. F. & Tolliday, N. J. Introduction: cell based assays for high-throughput screening. Methods Mol. Biol. 486, 1-12 (2013).
7. An, W. F. & Tolliday, N. J. Cell-based assays for high-throughput screening. Mol. Biotechnol. 45, 180-186 (2010).
8. LaBarbera, D. V., Reid, B. G. & Yoo, B. H. The multicellular tumor spheroid model for high-throughput cancer drug discovery. Expert Opin. Drug Discov. 7, 819-830 (2012).
9. Astashkina, A., Mann, B. & Grainger, D. W. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 134, 82-106 (2012).
10. Kenny, H. A. et al. Organotypic models of metastasis: a three dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat. Res. 149, 335-351 (2009).
11. Vorsmann, H. et al. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis. 4, e719 (2013).
12. Ridky, T. W., Chow, J. M., Wong, D. J. & Khavari, P. A. Invasive threedimensional organotypic neoplasia from multiple normal human epithelia. Nat. Med. 16, 1450-1455 (2010).
13. Berg, E., Hsu, Y. C. & Lee, J. A. Consideration of the cellular microenvironment: physiologically relevant co-culture systems in drug discovery. Adv. Drug Deliv. Rev. 69-70, 190-204 (2014).
14. Thoma, C. R. et al. A high throughput-compatible 3D microtissue co-culture systems for phenotypic RNAi screening applications. J. Biomol. Screen. 18, 1330-1339 (2013).
15. Frankel, A., Buckman, R. & Kerbel, R. S. Abrogation of taxol-induced G 2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular spheroids. Cancer Res. 57, 2388-2393 (1997).
16. Bae-Jump, V., Segreti, E. M., Vandermolen, D. & Kauma, S. Hepatocyte growth factor (HGF) induces invasion of endometrial carcinoma cell lines in vitro. Gynecol. Oncol. 73, 265-272 (1999).
17. Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053-1064 (2010).
18. Auersperg, N., Wong, A. S. T., Choi, K. C., Kang, S. K. & Leung, P. C. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr. Rev. 22, 255-288 (2001).
19. Levanon, K., Crum, C. P. & Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J. Clin. Oncol. 26, 5284-5293 (2008).
20. Kenny, H. A., Kaur, S., Coussens, L. M. & Lengyel, E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J. Clin. Invest. 118, 1367-1379 (2008).
21. Kenny, H. A., Krausz, T., Yamada, S. D. & Lengyel, E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells. Int. J. Cancer 121, 1463-1472 (2007).
22. Markman, M. Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Gynecol. Oncol. 131, 241-245 (2013).
23. Michael, S. et al. A robotic platform for quantitative high-throughput screening. Assay Drug Dev. Technol. 6, 637-657 (2008).
24. Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 103, 11473-11478 (2006).
25. Zhang, J. H., Chung, T. D. & Oldenburg, K. R. A simple statistical parameter for use in evaluation and vaidation of high throughput screeining assays. J. Biomol. Screen. 4, 67-73 (1999).
26. Oprea, T. I. et al. Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg. 8, 61-69 (2011).
27. Kenny, H. A. et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J. Clin. Invest. 124, 4614-4628 (2014).
28. Nieman, K. M. et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17, 1498-1503 (2011).
29. Kaur, S. et al. ß3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am. J. Pathol. 175, 2184-2196 (2009).
30. Kenny, H. A. et al. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin. Cancer Res. 17, 459-471 (2011).
31. Harikumar, K. B. et al. Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kB signaling pathway. Mol. Pharmacol. 77, 818-827 (2010).
32. Golan, T. et al. Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine. Br. J. Cancer 110, 2269-2276 (2014).
33. Place, A. E., Jin Huh, S. & Polyak, K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 13, 227 (2011).
34. Weroha, S. J. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288-1297 (2014).
35. Mitra, A. K. et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2, 1100-1108 (2012).